Myeloma UK is the only organisation in Great Britain exclusively dedicated to the disease
Rosemarie Finley, an experienced and accomplished healthcare leader, has been appointed Chief Executive of Edinburgh-based blood cancer charity Myeloma UK.
She’s set to join Myeloma UK on 28 June from the Epilepsy Society, where she was Acting Chief Executive and Chief Operating Officer.
Finley, who has an MBA in Health Management from City University Business School and has worked as a strategic adviser to a number of pharmaceutical companies, has more than 30 years’ management experience in the healthcare sector.
Also a trained nurse, she has held a number of senior leadership positions at Buckinghamshire Healthcare NHS Trust, including Director of Education for Research and Development; Associate Chief Nurse, Specialist Services Division; Safeguarding Lead, Acute and Community Services and Associate Director of Operations.
Judy Dewinter, Chairman of Myeloma UK, said: “I am delighted that Rosemarie is joining us as Chief Executive. She comes to us with a wealth of experience and a track record of strong leadership.
“Rosemarie combines her strong commitment to patients and the health and research agenda, with a clear understanding of the healthcare system and how to operate effectively within it. This is absolutely central to our work. The whole team looks forward to working with Rosemarie, as Myeloma UK enters a new and exciting phase in its journey.”
Finley added: “It is a privilege to be joining Myeloma UK, an organisation with a distinct reputation for putting patients at the heart of its strategy and for working collaboratively. I am looking forward to bringing my expertise of operating in highly complex healthcare environments to drive the organisation forward. Our aim will continue to be the acceleration of improved care, effective treatments and ultimately a cure for myeloma.”
Myeloma UK is the only organisation in Great Britain exclusively dedicated to myeloma, a type of blood cancer which affects plasma cells in the bone marrow. Its focus is on unlocking the potential for the development and delivery of new treatments, through primary research, strategic partnerships, education and campaigning.